Search
Search Results
##search.searchResults.foundPlural##
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2015PDF: 592Suppl. Files: 276HTML: 156 -
THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA. ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS
2222PDF: 950HTML: 63 -
QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA IN KERMAN-IRAN (I.R.)
1619PDF: 737HTML: 2331Cover Letter: 169 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2865PDF: 1566HTML: 222 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2146PDF: 1150HTML: 2575Study of serum haptoglobin level in thalassemia: 329Figures: 165 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2431PDF: 1126HTML: 11787 -
-
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2338PDF: 1564HTML: 599 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
219PDF: 166Suppl. Files: 33HTML: 6 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4188PDF: 1499HTML: 436 -
THALASSEMIA AND VENOUS THROMBOEMBOLISM
2889PDF: 1003HTML: 4569 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3121PDF: 1112HTML: 1469Untitled: 163Untitled: 152Untitled: 155 -
HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS
1377PDF: 480HTML: 3946 -
GENETIC HETEROGENEITY OF BETA GLOBIN MUTATIONS AMONG ASIAN-INDIANS AND IMPORTANCE IN GENETIC COUNSELLING AND DIAGNOSIS
1722PDF: 1267HTML: 11467Figure1: 161Figure 2: 162 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
2693PDF: 986HTML: 403TABLE: 174FIGURES: 228 -
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1059PDF: 474HTML: 8148 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1264PDF: 845HTML: 1025Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 162 -
-
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2641PDF: 1059HTML: 2559 -
Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia
712PDF: 524HTML: 144 -
A SEROPREVALENCE OF HBV, HCV AND HIV-1 AND CORRELATION WITH MOLECULAR MARKERS AMONG MULTI-TRANSFUSED THALASSEMIA PATIENTS IN WESTERN INDIA Incidence of serology & molecular of HIV, HBV and HCV in thalassemia patients
1295PDF: 749HTML: 479 -
HEMOGLOBIN ANALYSIS IN THE FIRST YEAR OF LIFE
3430PDF: 1008HTML: 3018 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2542PDF: 813HTML: 14934Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 283







